Dr. Grossbard on the Role of Maintenance Rituximab in Follicular Lymphoma

Video

In Partnership With:

Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.

Michael L. Grossbard, MD, professor in the Department of Medicine, chief of the Hematology and Medical Oncology Inpatient Service at Tisch Hospital, and section chief of Hematology at NYU Langone Health’s Perlmutter Cancer Center, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.

It is easy to get patients with follicular lymphoma into remission with all the new therapies that are available, says Grossbard. However, frontline therapy is not curative. Although maintenance rituximab can be used to prolong remissions, it may not impact long-term survival. Nonetheless, it is important for patients to be able to live free of disease and maintain their quality of life while on treatment, explains Grossbard.

The phase 3 PRIMA trial evaluated maintenance rituximab following induction chemotherapy with or without rituximab. Patients were treated until remission and then were randomized to receive no additional therapy or maintenance rituximab. Patients who had maintenance rituximab had longer remissions than those who did not receive maintenance therapy, concludes Grossbard.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD